Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

LAVAL, QC , May 6, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (Bausch Health) today announced its full leadership team and Board of Directors, including Chief Executive Officer (CEO) Thomas J. Appio.1 Upon completion of the initial public offering (IPO) of the Bausch + Lomb eye health business,2 former CEO Joseph C.

Bausch Health Announces Thomas J. Appio As Chief Executive Officer

Bausch + Lomb Corp

Bausch + Lomb, a well-known leader in eye care, is about to hit Wall Street in what investment bankers almost certainly hope will jump-start a weak initial public offering (IPO) market. Bausch Health Companies (BHC) is a global healthcare stock that develops pharmaceuticals, medical devices and over-the-counter medications, with focus areas in eye health, gastroenterology and dermatology.

Bausch + Lomb IPO: What You Need to Know

NOV03 Met Primary Endpoints for Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction in Both Phase 3 Trials VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany , May 3, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that data from the second pivotal Phase 3 trial (MOJAVE) of investigational treatment NOV03 (perfluorohexyloctane) were presented virtually yesterday at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. NOV03 is being investigated as a first-in-class treatment with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting

Here's what investors may want to know about the upcoming BLCO stock IPO, as Bausch + Lomb is split off from its parent company this week. The post BLCO Stock IPO: When Does Bausch + Lomb Go Public?

BLCO Stock IPO: When Does Bausch + Lomb Go Public? What Is the Bausch + Lomb IPO Price Range?

The U.S. initial public offering market is bracing for what is expected to be the second-biggest deal of the year so far this week, that of eyecare company Bausch & Lomb, which is expected to raise up to $840 million at a valuation of more than $8 billion.

IPO Report: U.S. IPO market bracing for second-biggest deal of the year so far in eyecare health company Bausch + Lomb

LAVAL, QC , April 29, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its first-quarter financial results on Tuesday, May 10, 2022. Bausch Health will host a conference call and live web cast at 8:00 a.m.

Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10

LAVAL, QC and VAUGHAN, ON , April 28, 2022 /PRNewswire/ -- Bausch + Lomb Corporation ("Bausch + Lomb"), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the launch of its initial public offering ("IPO") and the commencement of the roadshow for the IPO. A wholly owned subsidiary of Bausch Health (the "Selling Shareholder") is offering 35.0 million common shares of Bausch + Lomb.

Bausch + Lomb Corporation Announces Launch of IPO and Roadshow

LAVAL, QC and VAUGHAN, ON , April 28, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that, in connection with its previously announced intention to separate its eye health business, it has entered into an arrangement agreement with, among others, its wholly owned subsidiary Bausch + Lomb Corporation ("Bausch + Lomb"). The arrangement agreement sets out the terms and conditions of the proposed transactions by which Bausch Health currently expects to transfer all or a portion of the remaining direct or indirect equity interest in Bausch + Lomb following completion of the initial public offering of Bausch + Lomb (the "Bausch + Lomb IPO") and expiration or waiver of the IPO lockup to Bausch Health shareholders.

Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation

13 Poster Presentations Include Results from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane), as well as Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use VAUGHAN, ON and LAVAL, QC , April 28, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the presentation of 13 scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in Denver, Colo., from May 1-4, 2022, and virtually from May 11-12, 2022.

Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting

Four Poster Presentations Will Include New Analyses on ARAZLO® LAVAL, QC , April 27, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced the presentation of four poster presentations during the Florida Society of Dermatology Physician Assistants (FSDPA) 2022 New Wave Dermatology Conference, which will take place in Coral Gables, Fla. from April 28 - May 1, 2022.

Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference

NOV03 Met Both Primary Endpoints for Signs and Symptoms of Dry Eye Disease VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany , April 25, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that data from the first pivotal Phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD), was presented yesterday as part of a podium presentation on April 24, 2022, at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C.  "The data show that NOV03 met both primary endpoints of total Corneal Fluorescein Staining, a measure that assesses damage to the eye, and visual analogue scale dryness score at day 57," said Joseph Tauber, M.D.

Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting

VAUGHAN, ON and LAVAL, QC and TRENTON, N.J. , April 21, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 48,235,850 million units, or 290,145 pounds, of used contact lenses, eye care and lens care materials, which is the equivalent of the weight of approximately 31 elephants.1 Both programs are made possible through a collaboration with TerraCycle®, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste.

Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs

Bausch Health Companies has lost 25% of its equity value so far this year. Management continues to execute on their strategic alternatives plan to drive shareholder value.

Revisiting Bausch: $7.5B Market Cap Too Low

LAVAL, Quebec, and VAUGHAN, Ontario , April 20, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that, in connection with its previously announced intention to separate its eye health business (the "Separation"), its wholly owned subsidiary, Bausch + Lomb Corporation ("Bausch + Lomb"), is seeking to enter into a new credit agreement (the "Bausch + Lomb Credit Agreement"), which is expected to include a $2.5 billion term B loan facility (the "Term Loan Facility") and $500 million revolving facility (the "Revolving Credit Facility", and together with the Term Loan Facility, the "Credit Facilities"). The Term Loan Facility is expected to mature in 2027.

Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health

10 Podium Presentations, Two Posters Include Results from the First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) VAUGHAN, ON and LAVAL, QC , April 18, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the presentation of 10 podium presentations and two poster presentations during the American Society of Cataract and Refractive Surgery annual meeting, which will take place from April 22-26, 2022 in Washington, D.C. The presentations will include results from the first of two pivotal Phase 3 trials of the investigational treatment, NOV03 (perfluorohexyloctane), as well as from several studies involving the company's surgical technologies.

Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting

Featured Posters Will Include XIFAXAN® (rifaximin) and RELISTOR® (methylnaltrexone bromide) Research BRIDGEWATER, N.J. , April 7, 2022 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies Inc. (NYSE/TSX: BHC) and one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced today that four posters featuring data for XIFAXAN® (rifaximin) and RELISTOR® (methylnaltrexone bromide) will be presented at the Society of Hospital Medicine (SHM) Converge 2022 annual meeting taking place in Nashville, Tenn.

SALIX PHARMACEUTICALS WILL PRESENT SCIENTIFIC DATA AT THE SOCIETY OF HOSPITAL MEDICINE CONVERGE 2022

LAVAL, Quebec , April 4, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and disorders, today released the results from the second edition of its Patient Perspectives Survey, an annual survey of U.S adults living with irritable bowel syndrome (IBS) or chronic idiopathic constipation (CIC). The current report, Patient Perspectives: Living with IBS Now, offers a current understanding of the behaviors and experiences of the IBS and CIC patient population in the past year (February 2021 – February 2022), including insights on diagnosis and symptom management.

HALF OF IBS PATIENTS SURVEYED REPORT IBS SYMPTOMS MORE CHALLENGING TO MANAGE IN THE PAST YEAR

Global IPO volumes fell 37% during the first quarter of 2022 according to a study from EY.

Bausch & Lomb Files for IPO as Global Listing Volumes Slump

Bausch Health Cos. Inc. BHC, -0.56% filed for an initial public offering of its Bausch & Lomb Corp. unit on Thursday, with plans to list on the New York Stock Exchange, under the ticker "BLCO.

Bausch & Lomb files for IPO with plans to list on NYSE under ticker 'BLCO'

Bausch Health Cos. Inc. BHC, -1.05% said Tuesday it will reduce its debt by $200 million by paying down senior loans on March 31 using cash generated from operations.

Bausch to reduce debt by another $200 million by repaying senior loans on March 31

LAVAL, QC , March 29, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $200 million through the pay down of its senior secured term loans on March 31, 2022, using cash generated from operations. About Bausch Health Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.

Bausch Health Will Reduce Debt By $200 Million

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Bausch (BHC) Up 1% Since Last Earnings Report: Can It Continue?

Research Reveals Reduction in Hospitalization Rates, Length of Stay and Health Care Costs When Treating OIC with FDA-Approved Prescription Medications LAVAL, QC , March 24, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) "Bausch Health" and its gastroenterology business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced that Advances in Therapy  has published new health economic and outcome research revealing that patients who received prescription medications approved by the U.S. Food and Drug Administration (FDA) for opioid-induced constipation (OIC-Rx), including RELISTOR® subcutaneous injection (SC) (methylnaltrexone bromide), in the emergency department (ED) were less likely to be hospitalized, and when hospitalized, had a shorter length of stay than patients who did not receive an OIC-Rx in the ED. These findings highlight the potential for RELISTOR SC to provide relief for patients with OIC.

New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy

VAUGHAN, ON and LAVAL, QC , March 22, 2022 /PRNewswire/ -- Solta Medical Corporation ("Solta"), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), announced that Gary Gemignani will join as Chief Financial Officer (CFO), effective March 28, 2022. An accomplished health care executive with more than 35 years of financial and corporate strategy experience, Mr.

Gary Gemignani Will Join Solta Medical Corporation As Chief Financial Officer

Three Poster Presentations Will Include New Analyses on IDP-126 Gel, DUOBRII® and SILIQ® Company Will Introduce New JUBLIA® Virtual Reality Experience in Booth LAVAL, QC, March 22, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of three posters during the 2022 American Academy of Dermatology (AAD) Annual Meeting, which takes place March 25-29, 2022. The presentations will feature new analyses of the investigational medicine IDP-126 Gel and the efficacy of DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, as well as results from multiple studies assessing the efficacy of SILIQ® (brodalumab) Injection for the treatment of nail and scalp psoriasis.

News for Bausch Health Companies Inc Stock (BHC)